Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

Market Cap	11.28B
Revenue (ttm)	1.83B
Net Income (ttm)	490.68M
Shares Out	224.87M
EPS (ttm)	2.22
PE Ratio	22.56
Forward PE	19.30
Dividend	0.90 (1.79%)
Ex-Dividend Date	Jun 12, 2025

Volume	3,850,133
Average Volume	4,890,120
Open	50.09
Previous Close	50.13
Day's Range	49.54 - 50.42
52-Week Range	41.80 - 81.50
Beta	0.45
RSI	43.83
Earnings Date	Aug 22, 2025

About SHA:688076

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers APIs, including peptides, small molecules, and oligonucleotides; and intermediate products, such as fulvestrant, oseltamivir, and other intermediates. It also provides CRDMO/CMO services. The company was founded in 2009 and is headquartered in Hangzhou City, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 1,545
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688076

Financial Performance

In 2024, SHA:688076's revenue was 1.62 billion, an increase of 57.21% compared to the previous year's 1.03 billion. Earnings were 404.39 million, an increase of 148.19%.